Verona Pharma PLC Data on RPL554 to be presented at ERS Congress

 
TIDMVRP 
 
Verona Pharma plc 
 
                      ("Verona Pharma" or the "Company") 
 
   New clinical data on RPL554 to be presented at the 2016 ERS International 
                                   Congress 
 
  Detailed data from Phase 2a "add-on" trial as ??LATE-BREAKING 
                                   abstract" 
 
30 August 2016, Cardiff - Verona Pharma plc (AIM: VRP.L), the drug development 
company focused on first-in-class medicines to treat respiratory diseases, 
today announces that it will present three abstracts at the European 
Respiratory Society (ERS) 2016 International Congress in London, UK between 3-7 
September. The abstracts will cover clinical data related to the Company's lead 
drug, RPL554, a novel inhaled dual PDE3/PDE4 inhibitor with both bronchodilator 
and anti-inflammatory properties. RPL554 is currently in development as a 
nebulised maintenance treatment for chronic obstructive pulmonary disease 
(COPD) patients with moderate to severe disease and as a treatment for acute 
exacerbations in COPD patients in a hospital or home-care setting. 
 
Detailed results from the Company's Phase 2a "add-on" trial, where RPL554 
produced a statistically and clinically significant additional bronchodilation 
on top of standard of care bronchodilators in COPD patients, will be presented 
for the first time in an oral presentation, by Professor Dave Singh from the 
Medicines Evaluation Unit, University of Manchester, during a late-breaker 
session on Monday, 5 September 2016, at 11:00 in Room C. 
 
All three abstracts presented at ERS support Verona Pharma's view that RPL554 
could become an important, novel and complementary inhaled medicine for the 
treatment of respiratory diseases such as COPD, asthma and cystic fibrosis. In 
summary, the detailed data supports previously announced analysis of headline 
data which identified: 
 
  * Profound and sustained bronchodilation in healthy volunteers, COPD patients 
    and asthmatics; 
  * Comparable bronchodilation to high dose nebulised salbutamol (a standard of 
    care treatment) in asthmatics with fewer systemic effects; and 
  * Statistically and clinically significant improvements in lung function when 
    administered as "add-on" treatment to existing standard of care 
    bronchodilators in COPD patients. 
 
All abstracts and details on timings can be accessed through the ERS website: 
http://erscongress.org/ 
 
The title, timing and location of the abstract presentations are as follows: 
 
Abstract Number: 750050 
 
Authors:         D. Singh, K.H. Abbott-Banner, K. Newman 
 
Title:           LATE-BREAKING ABSTRACT: The novel inhaled dual PDE3/4 Inhibitor, 
                 RPL554, produces significant additional improvements in lung 
                 function when administered on top of existing standard of care in 
                 COPD patients 
 
Day/Date:        MONDAY, September 5, 2016 
 
Location:        Room C 
 
Time:            10:45 - 12:45 
 
Session:         Late-breaking topics in airways disease 
 
Session Type:    Oral Presentation 
 
 
 
Abstract Number: 851700 
 
 
Authors:         D. Singh, K.H. Abbott-Banner, K. Newman 
 
Title:           RPL554, an inhaled PDE3/4 inhibitor, causes profound and 
                 sustained bronchodilation in healthy volunteers and COPD patients 
 
Day/Date:        TUESDAY, September 6, 2016 
 
Location:        T-21 
 
Time:            12:50 - 14:40 
 
Session:         Novel avenues in the treatment of COPD 
 
Session Type:    Thematic Poster Session 
 
 
 
Abstract Number: 853133 
 
Authors:         L. Bjermer, J. Stewart, K. Abbott-Banner, K. Newman 
 
Title:           RPL554, an inhaled PDE3/4 inhibitor, causes comparable 
                 bronchodilation to high dose nebulised salbutamol in asthmatics 
                 with fewer systemic effects 
 
Day/Date:        WEDNESDAY, September 7, 2016 
 
Location:        Room ICC Capital Suite 8. 
 
Time:            8:30 - 10:30 
 
Session:         Novel mechanisms and treatment modalities in asthma 
 
Session Type:    Poster Discussion 
 
                                    -ENDS- 
 
About Verona Pharma 
 
Verona Pharma plc is a UK-based clinical stage biotech company focused on the 
development of innovative prescription medicines to treat respiratory diseases 
with significant unmet medical needs, such as chronic obstructive pulmonary 
disease (COPD), asthma and cystic fibrosis. 
 
Verona Pharma's lead drug, RPL554, is a first-in-class drug currently in Phase 
2 trials as a nebulised maintenance treatment for COPD patients with moderate 
to severe disease and possibly as a treatment of acute exacerbations of COPD in 
the hospital setting. The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor 
and therefore has both bronchodilator and anti-inflammatory effects, which are 
essential to the improvement of patients with COPD and asthma. 
 
Verona Pharma is also building a broader portfolio of RPL554-containing 
products to maximise its benefit to patients and its value. This includes the 
very significant markets for COPD and asthma maintenance therapy. The Company 
is also exploring the potential of the drug in different diseases, such as 
cystic fibrosis, where it is in pre-clinical testing and has received a Venture 
and Innovation Award from the Cystic Fibrosis Trust. 
 
About ERS 
 
The European Respiratory Society (ERS; www.ersnet.org) is an international 
organisation that brings together physicians, healthcare professionals, 
scientists and other experts working in respiratory medicine. It is one of the 
leading medical organisations in the respiratory field, with a growing 
membership representing over 140 countries worldwide. 
 
ERS's mission is to promote lung health in order to alleviate suffering from 
disease and drive standards for respiratory medicine globally. Science, 
education and advocacy are at the core of everything it does. 
 
THE 26th ERS International Congress will take place at London's ExCeL Centre 
and will host the world's largest and most influential meeting for respiratory 
physicians, scientists and allied health professionals. The Congress Scientific 
programme will present the best in science and educational sessions from 
distinguished researchers from across the globe. It will cover key topics in 
respiratory medicine from across the spectrum of disease areas including TB, 
lung cancer, pneumonia, cystic fibrosis, COPD and asthma amongst others. 
 
Further information on the congress can be accessed via the following weblink: 
http://erscongress.org/ 
 
For further information, please contact: 
 
Verona Pharma plc                      Tel: +44 (0)20 3283 4200 
 
Jan-Anders Karlsson, CEO 
 
N+1 Singer                             Tel: +44 (0)20 7496 3000 
 
Aubrey Powell / Jen Boorer 
 
FTI Consulting                         Tel: +44 (0)20 3727 1000 
 
Simon Conway / Stephanie Cuthbert / 
Natalie Garland-Collins 
 
 
 
END
(END) Dow Jones Newswires
August 30, 2016 02:00 ET (06:00 GMT)
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024